Drug intelligence / Profile preview

BMS-817399

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-817399 is a potent, selective, and orally bioavailable small molecule antagonist of the C-C chemokine receptor type 1 (CCR1). It was developed by Bristol Myers Squibb for the treatment of moderate to severe rheumatoid arthritis. The drug reached phase II clinical trials but development for this indication has been discontinued. Its mechanism of action involves blocking CCR1, a G protein-coupled receptor implicated in inflammatory processes[3][4][5][7][8].

Targets

CCR1

Beyond the preview

Go deeper on BMS-817399.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-817399.

Explore the full profile